Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2017

01-02-2017 | Research Article

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

Authors: J. De Castro, J. L. González-Larriba, S. Vázquez, B. Massutí, J. M. Sanchez-Torres, M. Dómine, P. Garrido, A. Calles, A. Artal, R. Collado, R. García, M. Sereno, M. Majem, J. A. Macías, O. Juan, J. Gómez-Codina, B. Hernández, M. Lázaro, A. L. Ortega, M. Cobo, J. M. Trigo, E. Carcereny, C. Rolfo, S. Macia, J. Muñoz, P. Diz, M. Méndez, F. Rosillo, L. Paz-Ares, J. V. Cardona, D. Isla

Published in: Clinical and Translational Oncology | Issue 2/2017

Login to get access

Abstract

Background/Aim

First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab.

Patients and methods

This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months.

Results

Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies.

Conclusion

Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
2.
Malvezzi M, Bertuccio P, Levi F, La VC, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2012;23(4):1044–52.CrossRefPubMed
3.
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.CrossRefPubMed
4.
5.
Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009;4(9):1094–103.CrossRefPubMed
6.
Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.CrossRefPubMed
7.
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–91.CrossRefPubMed
8.
Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2012;76(3):362–7.CrossRefPubMed
9.
Reck M, von PJ, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227–34.CrossRefPubMed
10.
Reck M, von PJ, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21(9):1804–9.CrossRefPubMedPubMedCentral
11.
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.CrossRefPubMed
12.
Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197–204.CrossRefPubMed
13.
Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11(8):733–40.CrossRefPubMed
14.
Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, et al. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the eastern cooperative oncology group 4599 study: results of an exploratory analysis. J Thorac Oncol. 2012;7(11):1707–12.CrossRefPubMed
15.
Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist. 2011;16(4):486–96.CrossRefPubMedPubMedCentral
16.
Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(1):20–30.CrossRefPubMed
17.
Berman RS, Portera CA Jr, Ellis LM. Biology of liver metastases. Cancer Treat Res. 2001;109:183–206.CrossRefPubMed
18.
19.
Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol. 2012;123(2):205–22.CrossRefPubMed
20.
Bar J, Goss GD. Tumor vasculature as a therapeutic target in non-small cell lung cancer. J Thorac Oncol. 2012;7(3):609–20.CrossRefPubMed
21.
Folkman J, Ryeom S. Is oncogene addiction angiogenesis-dependent? Cold Spring Harb Symp Quant Biol. 2005;70:389–97.CrossRefPubMed
22.
Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer TN, Kim JH, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31(24):3004–11.CrossRefPubMed
23.
Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013;31(31):3926–34.CrossRefPubMed
24.
Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(34):4349–57.CrossRefPubMedPubMedCentral
25.
Dansin E, Cinieri S, Garrido P, Griesinger F, Isla D, Koehler M, et al. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer. 2012;76(3):373–9.CrossRefPubMed
26.
Kosty MP, Brahmer JR, Jahanzeb M, Kumar P, Robles R, Wozniak AJ, et al. Use of bevacizumab (BV) after induction therapy is associated with survival benefit in patients (pts) with non-small cell lung cancer (NSCLC) in the ARIES observational cohort study (OCS). Eur J Cancer. 2011;47(Suppl. 1):598 (abstr. 9020).CrossRef
27.
Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, et al. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). J Thorac Oncol. 2014;9(6):848–55.CrossRefPubMed
28.
Massuti B, Jantus-Lewintre E, Gonzalez Arriba JL, Rodriguez Abreu D, Juan O, Domine M et al (2014) ANGIOMET: analysis of the correlations between angiogenic markers and outcome in patients (p) with advanced nonsquamous NSCLC (NS-NSCLC) treated with carboplatin, paclitaxel, and bevacizumab (CPB). J Clin Oncol 32, 2014 (suppl; abstr e19014).
Metadata
Title
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
Authors
J. De Castro
J. L. González-Larriba
S. Vázquez
B. Massutí
J. M. Sanchez-Torres
M. Dómine
P. Garrido
A. Calles
A. Artal
R. Collado
R. García
M. Sereno
M. Majem
J. A. Macías
O. Juan
J. Gómez-Codina
B. Hernández
M. Lázaro
A. L. Ortega
M. Cobo
J. M. Trigo
E. Carcereny
C. Rolfo
S. Macia
J. Muñoz
P. Diz
M. Méndez
F. Rosillo
L. Paz-Ares
J. V. Cardona
D. Isla
Publication date
01-02-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 2/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1527-8

Other articles of this Issue 2/2017

Clinical and Translational Oncology 2/2017 Go to the issue

Research Article

Proteomic modulation in breast tumors after metformin exposure: results from a “window of opportunity” trial

Clinical Guides in Oncology

Defining the optimal sequence for the systemic treatment of metastatic breast cancer

Research Article

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

Research Article

Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression

Research Article

Multiparametric evaluation of preoperative MRI in early stage breast cancer: prognostic impact of peri-tumoral fat

Special Article

SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits